CXC家族趋化因子水平对老年肺腺癌患者预后和化疗敏感性的影响

Effects of CXC family chemokine level on prognosis and chemotherapy sensitivity in elderly patients with lung adenocarcinoma

中文关键词: 老年  肺腺癌  预后  趋化因子

英文关键词: elderly  lung adenocarcinoma  prognosis  chemokine

中文摘要:

      目的 本研究旨在筛选预后相关的CXC家族趋化因子,并评估其表达水平对老年肺腺癌患者化疗敏感性的影响,以发掘潜在的预后标志,为个体化治疗策略制定提供参考依据.方法 选取2020年4月-2022年4月在空军军医大学第二附属医院治疗的老年肺腺癌患者的病例资料进行分析.检测患者血清CXC家族趋化因子水平(包括CXCL1-CXCL17).预后危险因素筛选采用单因素和多因素Cox分析.生存分析采用Kaplan-Meier曲线和Log-rank检验.结果 单因素Cox分析显示,CXCL17、CXCL16、CXCL13、CXCL8为肺腺癌患者预后良好的保护因素(HR＜1,P＜0.05).多因素Cox分析显示,CXCL17为肺腺癌患者预后良好的独立保护因素(HR=0.90,P=0.018).高CXCL17水平的肺腺癌患者预后优于低CXCL17水平的肺腺癌患者(P=0.013).在高CXCL17水平的肺腺癌患者中,接受化疗没有显著改善无进展生存期(P＞0.05).在低CXCL17水平的肺腺癌患者中,接受化疗可以显著改善无进展生存期(P＜0.001).在低CXCL17水平的患者中,化疗为肺腺癌患者预后良好的保护因素(HR=0.92,P=0.004).结论 CXCL17可能为肺腺癌患者预后良好的独立保护因素,高CXCL17水平预示着更长的无进展生存期.在低CXCL17水平的肺腺癌患者中,化疗是预后良好的保护因素.CXCL17可能是潜在的肺腺癌预后标志,可辅助分选适合化疗的患者,具有一定的临床应用价值.

英文摘要:

      Objective The purpose of this study was to screen prognostic related CXC family chemokines and evaluate the effect of their expression level on chemotherapy sensitivity in elderly patients with lung adenocarcinoma,so as to explore potential prognostic markers and provide reference for the formulation of individualized treatment strategies.Methods The case data of elderly patients with lung adenocarcinoma treated in Second Affiliated Hospital of Air Force Military Medical Uni-versity from April 2020 to April 2022 were selected for analysis.The level of serum CXC family chemokines(including CXCL1-CXCL17)were detected.The prognostic risk factors were screened by univariate and multivariate Cox analysis.Kap-lan-Meier curve and Log-rank test were used for survival analysis.Results Univariate Cox analysis showed that CXCL17,CXCL16,CXCL13 and CXCL8 were protective factors for good prognosis in patients with lung adenocarcinoma(HR＜1,P＜0.05).Multivariate Cox analysis showed that CXCL17 was an independent protective factor for good prognosis in patients with lung adenocarcinoma(HR=0.90,P=0.018).The prognosis of lung adenocarcinoma patients with high CXCL17 level was better than that of lung adenocarcinoma patients with low CXCL17 level(P=0.013).In lung adenocarcinoma patients with high level of CXCL17,chemotherapy did not significantly improve progression-free survival(P＞0.05).In lung adenocarci-noma patients with low level of CXCL17,chemotherapy could significantly improve progression-free survival(P＜0.001).In patients with low CXCL17 level,chemotherapy was a protective factor for good prognosis in patients with lung adenocarcinoma(HR=0.92,P=0.004).Conclusion CXCL17 may be an independent protective factor for good prognosis in patients with lung adenocarcinoma,and high CXCL17 level may predict longer progression-free survival.In lung adenocarcinoma patients with low CXCL17 level,chemotherapy is a protective factor for a good prognosis.CXCL17 may be a potential prognostic marker of lung adenocarcinoma,which can assist in the sorting of patients suitable for chemotherapy,and has certain clinical application value.